قارن الطرق

	دراسة المرحلة الرابعة المعدلة حسب المخاطر	مطابقة درجات الميل
المجال	علم الأوبئة	إحصاء البحث
العائلة	Process / pipeline	Process / pipeline
سنة النشأة	1990s–2000s (formalized with ICH E2E and EMA PASS guidelines)	1983
صاحب الطريقة	Regulatory and pharmacoepidemiology community (ICH, EMA, FDA frameworks)	Paul Rosenbaum and Donald Rubin
النوع	Observational / quasi-experimental clinical study design	Method
المصدر التأسيسي	Strom, B. L. (Ed.). (2005). Pharmacoepidemiology (4th ed.). John Wiley & Sons. ISBN: 978-0470863107	Rosenbaum, P. R., & Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1), 41–55.
الأسماء البديلة	risk-adjusted post-marketing surveillance study, adjusted Phase IV trial, risk-stratified post-authorization study, PASS with risk adjustment	PSM, propensity score weighting, covariate balance
ذات صلة	3	3
الملخص	A risk-adjusted Phase IV study is an observational or semi-experimental post-marketing study conducted after a drug or device has received regulatory approval. It uses statistical risk-adjustment techniques — such as propensity score matching, inverse probability weighting, or multivariable regression — to control for confounding by indication and baseline patient differences, thereby producing more credible safety, effectiveness, and utilization estimates than unadjusted real-world analyses.	Propensity score matching (PSM) is a method for reducing confounding bias in observational studies by balancing baseline characteristics between treatment groups, simulating randomization. Developed by Rosenbaum and Rubin (1983), it estimates the probability of receiving treatment given observed covariates, then matches or weights treated and control individuals with similar treatment probabilities. Widely used in medicine, epidemiology, and policy evaluation when randomized trials are infeasible or unethical, enabling estimation of treatment effects while controlling for selection bias.